Shares of several small-cap biotechnology companies rose sharply in U.S. pre-market trading after each reported favorable clinical or regulatory milestones. Praxis Precision Medicines jumped roughly 21% after unveiling topline results from its Phase 2 RADIANT trial showing Vormatrigine produced a 56.3% median reduction in focal-onset seizures, a result the company described as "best-in-disease." INmune Bio climbed about 22% when its Phase I/II CaRe PC study demonstrated that INKmune met predefined safety and efficacy endpoints in metastatic castration-resistant prostate cancer, prompting the company to close enrollment. Cassava Sciences advanced nearly 7% on positive preclinical findings for Simufilam in tuberous sclerosis complex–related epilepsy, while Exicure gained a similar amount after completing a Phase 2 trial of GPC-100 in multiple myeloma. Separately, Anixa Biosciences began the transfer of the FDA-cleared Investigational New Drug application for its Cleveland Clinic-partnered breast cancer vaccine as it prepares to move the program into Phase 2 testing.